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Purpose. Fragility fractures in men constitute a major worldwide public health problem with a life-time risk of 13%. It cannot
be directly inferred that antiosteoporotic drugs eﬀective in women have the same eﬀect in men. Our aim was to appraise the
existing evidence for eﬃcacy of osteoporosis treatment in men. Methods. This study was a systematic review of the published
literature on the clinical eﬃcacy of medical osteoporosis therapy in the reduction of fracture risk in men (age > 50 years). Studies
included were randomised, placebo-controlled trials of men. Results. Five BMD studies of antiresorptive treatment were included.
All studies showedan increase in BMD,but there wasonlya nonsigniﬁcanttrend in thereduction ofclinicalfractures. Three BMD
studies of anabolic treatment with teriparatide were also included. These showed a signiﬁcant mean increase in spine BMD and
for vertebral fractures a non-signiﬁcant trend towards a reduction was seen. Conclusion. The evidence of medical osteoporosis
treatment in men is scant and inconclusive due to the lack of prospective RCT studies with fracture prevention as primary end
point. So far, all evidence is based on BMD increases in small RCT studies showing BMD increases comparable to those reported
in postmenopausal women.
1.Introduction
Fragility fractures in men constitute a major worldwide
publichealth problem[1] althoughtheincidenceand gender
ratio varies between countries [2]. The life-time risk of any
fracture in the hip spine or distal forearm in men aged >50
years has been estimated to be 13% compared with 40% in
females [3] The fractures occur 5–10 years later in men than
in women [4], but the increasing longevity in men is likely
to increase the public health burden of the fractures [2].
Follow-up studies, including the osteoporotic fractures in
men (MrOS) cohort, have established that 1 SD deviation in
areal bone mineral density (aBMD) equally predict fracture
riskforspine andhipinmenandinwomen[2,5].Therefore,
the lower incidence of fractures in males compared with
females in all probability reﬂects that at any, age fewer males
than women have compromised biomechanical competence
because of smaller bones, lower volumetric BMD (vBMD),
thinner cortices, thinner trabeculae, microfractures with dis-
ruption of trabecular structure, or higher bone turnover [2].
Moreover, the etiology diﬀers between males and females.
Hypogonadism is a risk factor for osteoporosis in both
sexes, but the prevalence and progression of sexhormone
deﬁciency diﬀers. Testosterone deﬁciency is a risk factor
for male osteoporosis, whereas estradiol deﬁciency is a
triggering factor in both sexes. Furthermore, the inﬂuence
of environmental factors like alcohol, smoking, and risk of
falling may diﬀer between sexes. Because of the described
gender diﬀerences in risk factors, pathophysiology, and bone
structure, it cannot be directly inferred that anabolic or
antiresorptive drugs that preventBMD loss and osteoporotic
fractures in females [6–26]h a v et h es a m ee ﬀect in males.
However,onlyfewsmall randomizedcontrolledtrials(RCTs)
onthetreatmenteﬃcacyofantiosteoporoticdrugshavebeen2 Journal of Osteoporosis
performed in men. It is, therefore, important to appraise the
existing evidence of the impact of osteoporosis treatment in
elderly and old men.
2.Objectives
Thisisasystematicreviewandmeta-analysisofthepublished
literature on RCT studies of clinical eﬃcacy of antiresorptive
and anabolic therapy in the reduction of fracture risk in
elderly and old men. The following end points were used:
RCT studies on vertebral fracture reduction, nonvertebral
fracture reduction, and hip fracture reduction for men with
primary osteoporosis.
3.Materialsand Methods
3.1. Eligibility Criteria for Study Inclusion. Studies should
be randomised placebo-controlled trials of at least 12
months duration (anti-resorptive treatment) or of at least
6 months duration (anabolic therapy). The antiresorptive
medications included as exposure variables in the search
were strontium ranelate, bisphosphonates, denosumab, and
miacalcic. Strontium ranelate was here categorized as antire-
sorptive although there is growing evidence that it also may
exert anabolic properties. The anabolic treatments included
the truncated PTH(1–34) analog teriparatide and the full
length PTH(1–84) preotact. Of the bisphosphonates, we
included all commercially available medications for oral
or intravenous treatment. That is, etidronate, ibandronate,
risedronate, alendronate and zoledronate.
Only RCT studies where the primary end-points were
vertebral, nonvertebral or hip fracture risk reductions,
and/or BMD changes were included.
3.2. Search Methods. An electronic search of PubMed (1951
and onwards), Embase (1974 and onwards), ScienceCitation
Index (1945 and onwards), and the Cochrane Central
Register of Controlled Trials was performed. The search date
was December 19, 2010.
Abstracts of all possibly relevant articles were reviewed
for potential eligibility (assessed by P.Schwarz and P. Vester-
gaard). Discrepancies were solved through discussion. Those
deemed eligible and those that did not had adequate
information to conﬁrm their inclusion underwent a full text
review. The retrieval was based on published papers only.
We examined reference lists of retrieved studies for further
relevant publications. If several publications were reported
based on the same trial data we chose the report with the
longest followup. Pooled analyses and subgroup analyses
were not included due to their weak statistical value. No
contacts were made with lead authors or pharmaceutical
companies.
The keywords producing the majority of results, that is
“osteoporosis,” “treatment,” and “men” were chosen. This
search gave 10.314 trials (Table 1). Subsequently, a search
was made separately for each of the respective drugs. This
method did not produce any articles with fracture reduction
as end point in men, so the same search was repeated with
Table 1: Identifying key words.
Osteoporosis AND
Treatment AND
Men
10.314
AND alendronate 495
AND risedronate 215
AND ibandronate 63
AND didronate 300
AND zoledronic acid 127
AND strontium ranelate 50
AND denosumab 28
AND miacalcic 81
AND teriparatide 175
AND PTH(1–84) 17
AND preotact 1
BMD as a substitute endpoint for fracture risk reduction.
Concerning antiresorptive treatment, this method produced
13 potentialpapers of which 7 reported open-labelled and/or
not randomised studies, leaving 6 papers to be included.
As to anabolic treatment, 5 potential papers were identi-
ﬁed. However, one study only reported data with a mixture
of men and women without the possibility of extracting data
solely on men, leaving 4 papers for evaluation.
Alldataweresummarised inaformulaincludingnumber
of patients, age, gender, BMI, BMD, duration, and main
outcomes measured (Table 2).
3.3. Statistical Analyses. The meta-analysis was performed as
ar a n d o me ﬀects model using the inverse of the standard
deviation of the individual BMD and fracture risk parame-
ters from each study as weights for the estimates as proposed
by B¨ ohning [33]. Tests for heterogeneity and publication
bias were performed. P<0.05 was considered statistically
signiﬁcant.
4.Results
4.1. Antiresorptive Drugs. Five antiresorptive drugs, alen-
dronate (2 studies), risedronate (1 study), ibandronate (1
study),zoledronate(2studies),andnasal miacalcic(1study),
havebeeninvestigated inmalepopulationswithosteoporosis
(Table 2)[ 27–32, 34]. The study zoledronate study of Orwoll
et al.[32]wasexcluded,asit wasnot placebo-controlled,and
thezoledronatestudyofLylesetal.[34]wasamixtur eofmen
and women, and data on men could not be extracted. The
remaining ﬁve studies had BMD as their primary end-point
(Table 3).
4.1.1. Changes in BMD. Orwoll et al. [27]r e p o r t e da
signiﬁcant increase in bone mineral density of 7.1 ± 0.3%
at the lumbar spine, 2.5 ± 0.4% at the femoral neck, and
2.0 ± 0.2% for the total body (P<0.001 for all comparisons
with baseline). The increase in BMD in the alendronate
group was greater than that in the placebo group at allJournal of Osteoporosis 3
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Figure 1: Increase in spine (a) and femur (b) BMD in the Teriparatide studies by daily dose.
measurement sites (Table 3, P<0.001). In a 3-year RCT,
Gonnelli et al. [28]r e p o r t e da ni n c r e a s ei nl u m b a rs p i n e
BMD of 4.2% at year 1, 6.3% at year 2, and 8.8% at year
3. BMD at the femoral neck and total hip increased 2.1%
and 1.6%, respectively, at year 1, 3.2% and 2.9% at year 2,
and 4.2% and 3.9% at year 3. In a 2-year RCT Boonen et al.
[29] reported that treatment with risedronate resulted in a
signiﬁcant 4.5% (95% CI: 3.5–5.6%; P<0.001) increase in
lumbar spine BMD compared with placebo. In a 1-year RCT
study, Orwoll et al. [30] reported an increase inlumbar spine
BMD of 3.5% (P<0.001). BMD at the total hip increased
by 1.8% (P<0.001) and femoral neck 1.2% (P<0.012)
[30]. Trovas et al. [31] performed a 12-month RCT with
nasal miacalcic. The men who were treated with calcitonin
had a mean increase in BMD of 7.1 ± 1.7% at the lumbar
s p i n e .T h ei n c r e a s ei nl u m b a rB M Di nt h ec a l c i t o n i ng r o u p
was signiﬁcantly greater than that in the placebo group (P<
0.05).
4.1.2. Changes in Risk of Fractures. Three studies reported
fractures as secondary endpoints. All studies had included
few patientswith a lowmean age,and theyall had a relatively
short duration of 12–36 months (Table 2).
The studies of Orwoll et al. (alendronate) [27]a n d
Boonen et al. (risedronate) [29] both reported incidences of
vertebral fractures (Table 3). Orwoll et al. found a signiﬁcant
reduction (P = 0.02) in vertebral fractures determined
by quantitative methods and no eﬀect on non-vertebral
fractures. Boonen et al. found 2 new vertebral fractures
after 2 years each in the risedronate group. There was a
nonsigniﬁcant trend towards a reduction in all fractures
(placebo 6 patients (6.5%); risedronate 9 patients (4.7%)).
4.2. Anabolic Drugs. Five studies were available on anabolic
treatment with teriparatide in men [9, 35–38]. However, the
study of Finkelstein et al. was not placebo controlled and
therefore excluded [36], and the study of Kaufman et al.
was based on the same men as reported in the study of
Orwoll et al. [9] and therefore excluded as well. In addition,
a newly published study report on both Japanese men and
women was available [37]. However, data on men cannot be
extracted from this publication and the included numbers of
men were low (5 in the placebo group and 9 in the treatment
group), this study was excluded as well [37]. No studies
in men were available for preotact or any other anabolic
medication. In all three included papers, the primary end
point was BMD (Table 2).
4.2.1.ChangesinBMD. ComparedwithplaceboOrwolletal.
[9] found a signiﬁcant increase in lumbar spine (P<0.001)
and femoral neck (P = 0.029) BMD in the group receiving
20µg/day of teriparatide (Table 3). In the 40µg/day group,
the increase in BMD compared with placebo was signiﬁcant
at the lumbar spine (P<0.001), the total hip (P<0.001),
and the femoral neck (P<0.001). The increase was higher
in the 40µg/day than in the 20µg/day group at the lumbar
spine (P<0.001), the total hip (P = 0.009) and the femoral
neck (P = 0.023). In the PTH-treated group, Kurland et al.
[35] found a gain in lumbar spine BMD at 18 months of
13.5 ± 3.0% (P<0.001 compared with placebo), whereas
the increase in the femoral neck was 2.9 ± 1.5%(P<0.05)
(Table 3).
T h em e a ni n c r e a s ei nB M Di na l ls t u d i e s( n = 3) and
subgroups (n = 4 in 3 studies) combined was 0.58 ± 0.02,
P<0.01 for spine BMD Z-score and0.05 ± 0.01, P<0.01
for femoral neck Z-score (Figure 1).
4.2.2. Changes in Risk of Fractures. Orwoll et al. [9]r e p o r t e d
non-vertebral fractures as side eﬀects in 6 patients (3 among
147 placebo treated, 2 among 151 treated with 20 micro-
grams of teriparatide, and 1 among 139 treated with 40
micrograms of teriparatide). Kurland et al. [35]r e p o r t e d6 Journal of Osteoporosis
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data on the incidence of vertebral fractures (1 new fracture)
among 6 PTH treated and 2 patients among 12 placebo-
treated had new vertebral fractures (one and three new
fractures, resp.). In average, the studies of Orwoll et al. and
Kurlandetal.yieldedareductioninriskofvertebralfractures
of RR = 0.60, 95% CI: 0.29–1.22, P for heterogeneity0.71.
4.2.3. Adverse Events. Focusing on adverse events in the
anti-resorptive treatment group, the study of Orwoll et
al. [27] showed that the incidence of overall GI adverse
events was higher in the placebo group compared with
the risedronate group (18% versus 8%). Also, withdrawal
from the study because of adverse events was more frequent
in patients taking placebo (9.7% versus 3.7%) [29]. For
alendronate [27, 28], the results resemble the results in
women. In the miacalcic study [31], no speciﬁc data are
reported (Table 4). Among the anabolic studies, Orwoll et
al. [9] reported 2 deaths in the teriparatide 20µgg r o u p .
None of these was considered related to study drug or
procedures. Three cancers occurred in the placebo group,
threeintheteriparatide20µggroupandnoneinTeriparatide
40µg group. There were no cases of osteosarcomas. In the
two studies, it was concluded that the medication was well
tolerated [9, 35].
5.Discussion
There is evidence that both antiresorptive and anabolic
treatment compared with placebo increase BMD in osteo-
porotic males. However, fracture data in men are scant at
all sites (vertebral, non-vertebral, and hip fractures), and
there are no RCTs that evaluate antiresorptive or anabolic
osteoporosis treatment in men with fractures as primary end
point. Furthermore, studies with fractures as secondary end
points are inconclusive. As a consequence, there is at present
no well-established documented treatment for idiopathic
osteoporosis in men. However, the fact that one in ﬁve
men aged ≥50 years will suﬀer an osteoporotic fracture
during their lifetime underscore the necessity to appraise the
antifracture eﬃcacy of various treatment modalities in men.
Thestrengthofthisstudyisthesystematicinclusionofall
studies available in men receiving anti-resorptive treatment
as well as anabolic osteoporosis treatments.
The limitations are the very low number of studies
included in the meta-regression makes the evidence based
on the method limited. Not only are the number of studies
limitedandthefollow-uptimeshort,thepowerofthestudies
torevealsigniﬁcant eﬀectsonfractureriskis alsolowbecause
ofthelimitednumberofpatientsincluded.Duetothisweare
not able to deﬁnitely conclude if one medication is in favor
of others among men with primary osteoporosis.
In conclusion, the evidence of medical osteoporosis
treatment in men is scant at all sites and inconclusive due
to the lack of prospective large RCT studies with fracture
prevention as primary endpoint. All evidence so far is based
on BMD ﬁndings in small RCT studies showing increases
comparable to those observed in studies in postmenopausal
women.
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